Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Germany warns vaccinations alone will not contain COVID-19 third wave

Fri, 19th Mar 2021 12:41

* Spahn says doctors will now be more informed of risks

* Merkel to discuss speeding up rollout with state leaders

* Spahn says would favour supply deal for Russia's Sputnik V
(Adds details)

BERLIN, March 19 (Reuters) - Germany's health minister
warned on Friday there was not enough vaccine in Europe to
contain the COVID-19 third wave, as the country sought to get
its rollout back on track following a three-day pause in using
the AstraZeneca shot.

Case numbers have been rising in Germany, driven by an
easing of restrictions in recent weeks just as a more
transmissible variant of the virus has spread, underlining the
need to accelerate vaccinations to protect the vulnerable.

Health Minister Jens Spahn defended the suspension, which
was lifted on Thursday after European Union regulators said the
benefits outweighed the risk, as providing
transparency.

"We can reintroduce AstraZeneca but prudently with informed
doctors and appropriately educated citizens," he said in a
weekly news conference.

But he warned that vaccinations alone would not be able to
contain the third wave as there are not enough doses, and said
restrictions that were lifted may have to be reimposed to
contain the spread of the virus.

"The rising case numbers may mean that we cannot take
further opening steps in the weeks to come. On the contrary, we
may even have to take steps backwards," Spahn said.

State leaders are also due to discuss with Chancellor Angela
Merkel later on Friday ways to speed up the vaccination
campaign, among other by allowing family doctors to start
administering doses at their surgeries.

The suspension was the latest hurdle in Germany's
vaccination campaign, which has been plagued by delivery delays
and news reports of side-effects. As of Friday, just 8.5% of the
population had received a first shot, far behind other countries
like the United States and Britain.

German state leaders said they were ready to quickly catch
up on lost time. In Berlin, anyone who was due to receive an
AstraZeneca shot earlier in the week can turn up at vaccination
centres this weekend without an appointment.

YOUNGER WOMEN

Meanwhile, the premier of the southwestern German state of
Baden-Wuerttemberg, Winfried Kretschmann, 72, is due to receive
an AstraZeneca vaccination on Friday, in a move to shore up
confidence.

But Bodo Ramelow, the premier of Thuringia in eastern
Germany, said he would not advise his wife, who needs to use
blood thinners due to a risk of thrombosis, to get the
AstraZeneca shot although he would do so himself.

Karl Lauterbach, the main health expert of the SPD, Merkel's
junior coalition partner, said it was important to not create
the impression that the AstraZeneca vaccine was not suitable for
younger women.

In Germany, eight people were diagnosed with cerebral venous
sinus thrombosis (CVST) within about two weeks of being
vaccinated. They were among the 1.6 million recipients of the
shot as of Wednesday, with CVST cases higher among women.

Lauterbach said the higher incidence could be due to the
fact that younger women work in the health sector or in
kindergartens, groups that have received the AstraZeneca vaccine
in higher numbers.

Spahn said he hoped vaccinations could take place in
doctors' practices from April 19 at the latest, but warned that
supply would remain restricted.

Germany expects to receive 15 million doses of the
AstraZeneca vaccine in the second quarter, a few million fewer
than initially expected, he said.

Spahn also spoke out in favour of signing a supply deal for
the Russian Sputnik V vaccine for COVID-19, but said there
needed to be greater clarity on the quantities available.

(Reporting by Caroline Copley; Editing by Maria Sheahan and
Paul Simao)

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.